Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives


Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women’s health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women’s health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.

See end of article for authors’ affiliations

Correspondence to: Professor N Krieger, Department of Society, Human Development and Health, Harvard School of Public Health, Kresge 717, 677 Huntington Avenue, Boston, MA 02130, USA; nkrieger@hsph.harvard.edu

Accepted for publication 27 May 2005

Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial of HRT, the women’s health initiative (WHI),\(^1\) conducted in a population of mainly healthy women, indicated that long term use of the combined oestrogen plus progestin HRT not only was associated with increased risk of breast and ovarian cancer but, contrary to expectations, did not decrease, and may in fact have increased, risk of cardiovascular disease. Similar results were reported in 1998 by the smaller heart and estrogen/progestin replacement study (HERS), conducted among women with a history of cardiovascular disease.\(^2\) Together, these findings were treated as unexpected in both the scientific literature\(^1\) and popular media,\(^4,5\) given nearly four decades’ worth of recommendations, based on clinical experience, laboratory research, and observational epidemiological studies, for using HRT to stave off ill effects of aging and to prevent cardiovascular disease.\(^6-11\)

Immediate consequences of the alarming new HRT findings included a dramatic decrease in prescriptions and marketing of HRT in the USA (for example, by 33% for estrogen plus progestin, by 18% for estrogen alone)\(^10-13\) and other countries.\(^14\) Moreover, within both the clinical and epidemiological literature, sharp debates swiftly broke out—and continue—regarding the reasons for the different findings of the prior studies and the new investigations.\(^1-24\)

Contending explanations for the discrepancies, whose testing in future epidemiological research will probably yield new insights into the harms and benefits of HRT for women’s health, include: (1) confounding in observational studies unmasked by use of randomised clinical trials (for example, women prescribed HRT tend to be healthier and more affluent, and thus at lower risk of cardiovascular disease, resulting in spurious associations between HRT and reduced risk of cardiovascular disease); (2) selection by indication (for example, some physicians, aware of concerns about cardiovascular effects of contraceptives, may have been less likely to prescribe HRT to women at higher risk for cardiovascular disease); (3) use of the wrong study population in the clinical trials (older women past menopause (WHI mean age = 63.3 years)), thereby precluding assessment of HRT use only during the menopausal transition on subsequent disease risk); (4) use of different formulations and doses of HRT in diverse studies; and (e) methodological problems in detecting acute increases in risk (for example, of a heart attack) in observational cohort studies designed to collect data only once every two years.\(^3,4,17-24\)

The current debates over HRT would suggest that serious concerns about use of HRT are a novel phenomenon. They also imply that current scientific awareness of possible risks associated with HRT is attributable chiefly to scientific progress, with new studies debunking old ideas.

Abbreviations: HRT, hormone replacement therapy; WHI, women’s health initiative; HERS, heart and estrogen/progestin replacement study.
Such a rendering of the scientific discourse, however, is grossly inaccurate. In fact, biological, clinical, and epidemiological evidence emphasising risks and discounting purported benefits associated with what is now conventionally termed HRT has been published for well over a half century (table 1).

At issue, then, is not simply the “advance” of scientific knowledge—but also why decades of repeated warnings about dangers of manipulating and prescribing hormones to “treat” menopause were ignored and not translated into health policies.

To begin to address the question of why the WHI and HERS results were perceived and depicted as “shocking,” and to consider the implications for research and practice regarding women’s health and use of sex hormones as pharmacological agents, in June 2004 a group of historians, epidemiologists, biologists, clinicians, and women’s health advocates gathered for a two day interdisciplinary and comparative exploratory symposium on hormones, women, and cancer risk: professionals and activists facing “miracle hormones” and cancer risk: professionals and activists facing “miracle molecules” held at the Radcliffe Institute for Advanced Studies in Cambridge, MA (USA). The initial idea for the symposium was proposed by Dr Irena Lovy, and it was co-organised by Professor Nancy Krieger. Each group presented and invited discussion on its analysis of key issues regarding HRT use (table 2). Perhaps the outstanding lesson, delineated in table 2, is the necessity of framing contemporaneous scientific research and policy in historical, social, economic, and political context, so as to illuminate the oft concealed technical, administrative, economic, and political decisions and values that shape scientific inquiry and its impact on population health.

DISCIPLINARY INSIGHTS: HRT AND HISTORY, WOMEN’S HEALTH ADVOCATES, EPIDEMIOLOGY, BIOLOGY, AND CLINICAL MEDICINE

History

Reminding participants that use of hormones as pharmacological agents has never been without controversy, the historians presented a picture of three waves of debate about oestrogen use during the 20th century. The first occurred in the 1930s, once laboratory techniques succeeded in making oestrogens available as a manufactured drug.

During this period, biochemists and endocrinologists conducted animal experiments that provided evidence of the carcinogenicity of sex hormones; for clinicians, these studies translated to debates about the correct dose to be given, as hormones were viewed as “natural” and thus not intrinsically harmful.

The second wave occurred in the 1960s and 1970s, triggered by new health concerns about oral contraceptives, oestrogen only HRT and risk of endometrial cancer, plus the carcinogenicity of tobacco and environmental pollutants. The third wave is currently underway, and involves both concerns about the carcinogenicity of HRT and disputes over its presumed long term health benefits, including reducing risk of cardiovascular disease.

Noting changing participants and data over time, the historians described how the first wave principally involved laboratory scientists and clinical specialists in endocrinology and gynaecology. Their disputes were largely restricted to scientific and clinical journals, did not include either patients or the popular press, and were based on studies conducted among small samples of women. By contrast, in the second and third wave, women as patients and health advocates, along with regulatory agencies and the popular press, engaged as active participants. Additional medical subspecialities (cardiology, gerontology, oncology) also joined in; industry exerted a far greater influence on both pharmacological research and public discourse (for example, Ayerst, a leading pharmaceutical company, underwrote Wilson’s 1966 best selling pro-HRT book Feminine Forever).

More data were available from both hospital based studies and cancer registries. The net effect was to create a far more visible debate, with more participants and higher stakes.

Historical analysis additionally shows that the prominence and views of different sectors in the debate have varied within and across countries, within and over time. During the second and third waves, for example, French feminists and gynaecologists, who in France were principally women, plus women in the UK, were more positive toward hormone use than their US counterparts, with both patients and physicians supporting use of HRT to relieve symptoms; the French physicians also valued evidence of physiological mechanisms more than results of large scale clinical trials that minimised attention to individual variations in response to HRT.

Industry interest in plus government regulation of prescription of sex hormones has also intensified over time, with concern typically focused more on preventing harm than establishing benefits (especially long term benefits not detectable without lengthy follow up), efforts to couch arguments for HRT in terms of chronic disease “risk reduction” is a comparatively recent development. Thus, while there is no one single debate about use of HRT, similar themes are evident in all of the controversies, spanning

<table>
<thead>
<tr>
<th>Decade</th>
<th>Key issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>1930s</td>
<td>The commercial production and sale of hormones as drugs was accompanied by debates on the potential danger of induction of malignancies.</td>
</tr>
<tr>
<td>1940s–1950s</td>
<td>Doubts on the safety of menopausal hormones. Premarin is nevertheless a commercial success, as women increasingly began to use menopausal hormones.</td>
</tr>
<tr>
<td>1960s</td>
<td>Changes in women’s status and life expectancy encourage menopausal therapy: publicisation of Feminine forever (1966). HRT is presented as a therapy that allows women to free themselves from the maladies of oestrogen loss, and to conserve femininity.</td>
</tr>
<tr>
<td>1970s</td>
<td>The rise of women’s movement and women’s health movement. Rise of feminist criticism of the pill and of HRT, especially long term benefits not detectable without lengthy follow up.</td>
</tr>
<tr>
<td>1980s</td>
<td>The widespread introduction of progestin-oestrogen treatment for women with an intact uterus. HRT is increasingly presented as a preventive drug: “young and sexy forever.”</td>
</tr>
<tr>
<td>1990s</td>
<td>The steady increase in HRT uptake continues. This treatment is strongly promoted by most of doctors, and sustained, especially in the USA, by the ethos of individualised preventive medicine. The first large scale randomised prospective clinical trial of menopausal hormones— starts, partly as an answer to feminist criticism of HRT.</td>
</tr>
<tr>
<td>2000s</td>
<td>HER results on cardiovascular disease are surprising. Early interruption of WHI, after the finding of an excess of cancers and cardiovascular incidents in the experimental branch. In 2002–2003, a sharp decrease in HRT prescriptions in English speaking countries.</td>
</tr>
</tbody>
</table>
nearly 70 years and involving production, prescription, marketing, use, regulation, and availability of data to test claims of harms and benefits of pharmacological products.

**Women’s health advocates**

The women’s health advocates in turn highlighted the role of advocacy in uncovering hidden risks of pharmacuals routinely marketed for and to women, especially in relation to reproductive health.4 5 50 Recounting the founding of the National Women’s Health Network in 1975 and its origins in the civil disobedience by women’s health activists at the 1970 US Senate hearing on the birth control pill (for which no women patients had been asked to testify),59 60 the activists strongly supported the 1977 decision of the Food and Drug Administration (FDA) to make mandatory patient informed consent, full disclosure, and the demand that women—as the intended users of HRT and other drugs affecting women’s reproductive systems—have an active role in shaping the development, testing, and regulation of these drugs.

In their view, the experience with HRT underscored the political clout of the pharmaceutical industry and its manipulation of “consumer” fears and desires as “choice.” These companies had privileged access to women through their physicians, and to physicians and researchers through funding of conferences, training programmes, and research. The industry also drew on ethnographic techniques to identify key opinion leaders who could shape physicians’ and patients’ attitudes to—and receptivity towards—the pharmacological use of sex hormones (pages 115–5557). Together, the pharmaceutical companies, physicians, and researchers effectively colluded to promote the view that menopause is a “deficiency disease,” and that women needed long term treatment with HRT to prevent illness, loss of sexuality, and ugly aging.52 53 55 61 62 Use of drugs shifted from being “curative” to being a tool of “risk management,” requiring long term administration to an ever-expanding—and hence profitable—market of aging users.4 43 65

The initial demand of the women’s health movement—that women have control over and become knowledgeable about their own bodies—thus was diluted and subverted into a tightly medically supervised activity of testing for disease or pre-disease and “choosing” from an array of drugs and tests controlled by physicians and the pharmaceutical industry. The drugs themselves likewise took on a life of their own, as products to be marketed, such that when HRT use declined because of fear of endometrial cancer, new reasons needed to be found for their prescription. Thus, low bone density (“osteopenia”), previously just one of many risk factors, was reframed as the very definition of osteoporosis; this condition, only detectable with new technologies, provided a new rationale for long term prescription of HRT to menopausal women (pages 145–7669).

While highlighting the importance of unmasking risks of various specific drugs intended to regulate women’s reproductive health, the advocates also emphasised the need to consider the broader question of drug uptake in the context of the marketing imperatives of pharmaceutical companies, drug regulation, and the overall structure of the health care industry.5 53 66 67 In this process, the activists have engaged repeatedly with regulatory agencies; in the USA, for example, activists strongly supported the 1977 decision of the Food and Drug Administration (FDA) to make mandatory patient

---

**Table 2** Key issues relevant to debates over use of HRT from different disciplinary perspectives: history, women’s health advocates, epidemiology, biology, and clinical medicine

<table>
<thead>
<tr>
<th>Discipline</th>
<th>Key issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>(1) Disciplinary boundaries affecting understanding and awareness of risk.</td>
</tr>
<tr>
<td></td>
<td>(2) Definition, production, and use of pharmaceutical substances.</td>
</tr>
<tr>
<td></td>
<td>(3) Definition and practice of medical subspecialties.</td>
</tr>
<tr>
<td></td>
<td>(4) Comparative histories of medical practice.</td>
</tr>
<tr>
<td></td>
<td>(5) Impact of previous and contemporary medical and public health debates on HRT use.</td>
</tr>
<tr>
<td></td>
<td>(1) “Expose the abuse, critique the science, light the fire”: critical role of women’s health advocates.</td>
</tr>
<tr>
<td></td>
<td>(2) Political clout of pharmaceutical industry and manipulation of “consumer” fears and desires as “choice.”</td>
</tr>
<tr>
<td></td>
<td>(3) Contrast between “curative” and “risk management” treatments.</td>
</tr>
<tr>
<td></td>
<td>(4) Role of medical-industrial complex in manufacturing and marketing drugs for profit.</td>
</tr>
<tr>
<td></td>
<td>(5) Debates on drugs rarely linked to debates over structure of health care system.</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>(1) Inadequate use of appropriate study design (RCT), over-reliance on observational data, disregard for RCTs not favourable to HRT, and poor interpretation of epidemiological studies.</td>
</tr>
<tr>
<td></td>
<td>(2) Disregard of socially patterned confounding, via a vis who does and does not take HRT.</td>
</tr>
<tr>
<td></td>
<td>(3) Disregard for risk in relation to age (risk of breast cancer greater than coronary heart disease among women in their 40s and 50s), and discounting of adverse risk of breast cancer relative to risk reduction for cardiovascular disease.</td>
</tr>
<tr>
<td></td>
<td>(4) Disregard for distinctions between absolute and relative risk.</td>
</tr>
<tr>
<td></td>
<td>(5) Impact of pharmaceutical industry on epidemiological research, including emphasis on alleged benefits over risks and revised view of “acceptable risks” for healthy populations.</td>
</tr>
<tr>
<td>Biology</td>
<td>(1) Hormones by definition are global signalers in the body, such that “side effects” of hormonal therapies are inevitable.</td>
</tr>
<tr>
<td></td>
<td>(2) Steroid hormones affect more than the reproductive system and are involved in cell growth and differentiation, as well as immunity, metabolism, and behaviour.</td>
</tr>
<tr>
<td></td>
<td>(3) Endogenous and exogenous hormones, including xenosterogens, are typically studied in systems that show only a small portion of their biological activity.</td>
</tr>
<tr>
<td></td>
<td>(4) Ignorance vastly exceeds knowledge about the full range of biological functions of endogenous hormones and exogenous hormone-like agents.</td>
</tr>
<tr>
<td></td>
<td>(5) The complexity of biological systems precludes accurate quantitative “risk assessment” and is not compatible with non-precautionary “command and control” approaches to regulating and licensing safe levels of individual chemicals.</td>
</tr>
<tr>
<td>Clinical medicine</td>
<td>(1) Among the wealthier countries in which pharmaceutical companies have their principal markets, the pharmaceutical industry increasingly underwrites conferences and research, plus offsets journal costs through extensive advertising.</td>
</tr>
<tr>
<td></td>
<td>(2) In these same countries, the “best selling” drugs currently are “risk reducing” drugs, consonant with an increasing trend to focus on eliminating individual risk.</td>
</tr>
<tr>
<td></td>
<td>(3) Limited time, low reimbursement for counselling (cognitive services), and defensive medicine shape medical practice, increasing medical conformity and encouraging physicians to prescribe “risk reducing” drugs.</td>
</tr>
<tr>
<td></td>
<td>(4) Clinical guidelines encourage physicians to prescribe treatments even if there is not conclusive evidence that drugs are the best way to approach risk reduction.</td>
</tr>
<tr>
<td></td>
<td>(5) Until recently, physicians in the USA were encouraged at least to counsel women about the use of HRT as a standard of care for women during and after menopause, but have now been discouraged from routinely prescribing it.</td>
</tr>
</tbody>
</table>
packet inserts for oestrogens and likewise were instrumental in challenging the widely sanctioned use of HRT for unproven indications, for example, protection from cardiovascular disease.45 50 56 By questioning the economic and political agendas behind the growing medicalisation of women's reproductive lives and health, as exemplified by the saga of HRT, the women's health advocates hoped to re-ignite a focus on the fundamental question of the social, political, and economic conditions needed for all women to be able to enjoy reproductive and sexual autonomy, live healthy lives, age with dignity, and die with minimal suffering.

Epidemiology
Recognising the centrality of epidemiological evidence to arguments in favour of and against HRT use, the epidemiologists focused on debates over and changes in the epidemiological data on links between hormones, cancer, and cardiovascular disease.17–24 33–40 At issue was not only the quality and interpretation of epidemiological studies, but also beliefs about the role of sex hormones in women's and men's health.

Thus, starting in the late 1920s and early 1930s, UK and US epidemiological studies began to implicate endogenous sex hormones in breast cancer, by detecting links between risk of breast cancer and women's reproductive history (for example, age at menarche, nulliparity, age at first pregnancy, number of children, etc.).48–50 In the mid-20th century, concerns about the rise in coronary heart disease mortality, occurring at an earlier age among men than women, led to the presumption (bolstered by laboratory evidence49) that endogenous sex hormones were key to differences in women's and men's cardiovascular health71 72 and thus that use of oestrogens might reduce risk of cardiovascular disease.10 Simultaneously, the increasing proportion of women living longer after menopause (because of declines in deaths from childhood infectious disease and from maternal mortality) raised new questions about women's healthy aging.73 74

Starting in the mid-1970s, some epidemiologists began questioning HRT's presumed cardiovascular benefits. During the early 1970s, the oestrogen treatment arms of the coronary drug project, a clinical trial of HRT among men only for cardiovascular disease prevention, started in the mid-1960s, were discontinued because of increased adverse cardiovascular outcomes among the men receiving oestrogen.49 51 Concomitantly, epidemiological research linked rising use of HRT to rising rates of endometrial cancer.70–72 By the mid-1980s, some epidemiologists were noting that women who took HRTs were, from the outset, generally healthier—and more affluent—than women who did not.11 These cautionary findings, however, were dwarfed by the proliferation of studies favourable to HRT, while RCTs providing contrary evidence were downplayed and even disregarded.73 Also ignored were epidemiological data showing that the absolute risk of breast cancer was higher than that of cardiovascular disease among younger women, particularly among the great majority who are non-smokers, such that women were in fact at higher risk of breast cancer than men.70 110–112 Concern about the impact of HRT on carcinogenesis thus needs to be coupled with investigation of the impact of exposure to xenosterogens across the life course, starting with conception—if not before, given possible effects on germ cells and gametes.96 108

Importantly, difficult as it may be to measure the exact timing and dose of HRT exposure, recording and quantifying exposure to myriad hormonally active substances—in the food supply, air, water, and consumer products—is even more challenging. Relevant exposures may extend back to in utero and, making long term tracking complicated, only some xenohormones persist within the body, whereas others are quickly metabolised and excreted.92–95 113–115 The complexity of human endocrinology—which is characterised by feedback and feedforward dynamics, pleiotropy, plasticity, and combinatorial effects—defies simple “cause and effect” predictions.116 Consequently, for the foreseeable future, efforts to minimise chemical induced health and environmental risks will be based on incomplete knowledge. Strategies that require proof or fine scale predictions of specific links between individual chemicals and health risks before restrictive action can be taken are unlikely to be effective prevention policies.116–118 An alternative approach, known as the precautionary principle, posits that chemicals and
processes that may plausibly result in irreversible and/or widespread damage to health and ecosystems should be presumed hazardous until proved otherwise and should be avoided entirely if safer, more ecologically sustainable alternatives are available or can be developed.94 99 116–120

Clinical medicine
Physicians have enormous power to affect their patients’ lives and in turn powerful forces influence physicians. As the clinicians recounted, among these are the ethical imperative to “first do no harm” and to provide the best care possible, plus their socialisation in medical school to be authorities on human biology and behaviour. Also critical, especially in the USA (given its lack of national health insurance) are financial incentives that emphasise payment for acute care in hospital settings, reward physicians for seeing more patients in a limited time, and devalue training and reimbursement for preventive care,121 combined with the threat of malpractice. Moreover, despite efforts to prohibit drug company giveaways and open access to physicians in the clinical setting, “risk reducing” drugs have become “best sellers” via such strategies as the pharmaceutical industry’s sponsorship of physician education and direct to consumer marketing.57 58 122 Importantly, the pool of potentially “at risk” persons to whom preventive drugs can be sold far exceeds the number of persons clinically diagnosed with disease, and prescribing pills is more profitable than promoting behavioural and social changes that could potentially reduce risk.123

In the case of HRT, these different influences converged to the point where prescribing HRT became the standard of care, as a form of “preventive medicine”124 with many physicians believing it improved women’s wellbeing and quality of life,68 69 especially given longer life expectancy and greater risk of disabling disease after menopause. Despite concerns about possible bias in the observational studies toward healthy women and reports of increased breast cancer risk among women taking HRT, physicians nevertheless accepted the argument women should take HRT because of the much higher prevalence of cardiovascular disease compared with breast cancer. Conflicting reports, recommendations, and clinical guidelines about the use of HRT,125–127 coupled with women’s requests for HRT, limited time for office visits, and limited reimbursement for patient counselling likewise contributed to the rise of HRT prescribing. With patients increasingly recast as “consumers,” and physicians as “gatekeepers” to medications, for physicians to express scepticism about HRT was tantamount to denying their patients “choice”—a substantive as well as ideological breach of mainstream market mentalities in which health care is a commodity, not a social good.

After the results of the WHI were reported physicians quickly changed their prescribing habits related to HRT.10–11 Prescriptions plummeted and many women found themselves having to ask for prescriptions to treat extremely uncomfortable hot flashes or because they did not feel well without the drug treatment. The overwhelming evidence for increased breast cancer risk for women who remained taking the combined oestrogen plus progesterin HRT for five or more years and the increased risk of stroke, acute coronary syndromes, and thromboembolic disease persuaded many physicians to recommend that their patients stop HRT. Also influencing physicians was the potential threat of medical malpractice if they continued to prescribe the drugs. The dramatic change in prescribing practices, coupled with the lack of time to spend with patients to have informed discussions about the benefit and harms of taking HRT and continued uncertainty about best practices to manage menopausal symptoms,128 left many women, who ultimately have the right to make their own benefit-harm decisions, wondering what to do.130

REFRAMING THE HRT DEBATES: THE BENEFITS OF AN INTERDISCIPLINARY DIALOGUE
Yet, despite the complexities highlighted throughout the interdisciplinary dialogue and debate at our seminar, most mainstream discussion of HRT present the recent revelations that HRT may harm rather than benefit women’s health as a case of science “doing it right,” meaning that new evidence overturned prior ill founded and untested beliefs, one instance among many in the progress of human knowledge. This superficial reading, however, masks five important elements that together show the scientific enterprise is not simply a neutral or self correcting endeavour.

Missing element number 1: the invisible industrialist
As evident from each disciplinary perspective, throughout the 20th century, industry has played a critical part in the development and interpretation of scientific knowledge about the effects of hormones on health: endogenous hormones, exogenous hormones manufactured as pharmaceutical products, and most recently, endocrine disruptors, as described above. Its influence has been achieved not only through the direct funding and control of research, but also by funding the training and continuing education of scientists and physicians alike. These latter practices, however, are rarely if ever regulated by governments, which instead chiefly have been concerned with regulating marketing of pharmaceutical products and providing funds for basic research critical for industrial science. Together, these
priorities have fuelled the rise of a subsidiary biomedical industry involving the conduct of clinical trials and clinical epidemiology.

Missing element number 2: regulatory agencies and public compared with private interests

Governmental agencies, such as the US FDA, the UK Committee for the Safety of Medicines (CSM) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, and, recently, France’s Agence française de sécurité sanitaire des produits de santé (Afssaps, founded in 1998), have played a key—and at times contradictory—part in the HRT story. The 1977 FDA requirement for a patient package for oestrogens, including HRT, which the US Pharmaceutical Manufacturers Association fought in the courts (and lost), was probably one of the reasons for the decline in HRT sales in the late 1970s and early 1980s.4 131 FDA staff likewise played an important part in events leading to conduct of the WHI, and since publication of the WHI results 2002, the FDA, along with the CSM, MHRA, and Afssaps have been actively disseminating information about health impacts of hormone use to both health professionals and users of health services.82 83 135–139 Yet, until recently, these same regulatory agencies effectively permitted the ever widening "off label" use of HRT among women, for example, for untested claims regarding prevention of cardiovascular disease, in part because of the influence of pharmaceutical companies.4 50 57 58 To understand the complex and contradictory actions of the regulatory agencies, more transparency about the role of private interests affecting the public interest is required.

Missing element number 3: beliefs regarding individual compared with collective risk

Contemporary biomedicine focuses on the management of individual risk, construed as consequence of individual "lifestyles" combined with genetic predisposition, while effectively ignoring societal risks that shape changing population profiles of disease and social inequalities in health.65 83 135–139 In the case of HRT, the emphasis on individual risk contributed to research that ignored women's social and ecological context, thereby hindering rigorous analysis of socially patterned confounding and the possible impact of endocrine disruptors.

Missing element number 4: the irresistible growth of "preventive medicine"

A focus on individual risk, combined with a commercial imperative—for industry and physicians alike—to promote pharmacological products that could be used by broad sectors of the population for long periods of time, in turn has led to mass marketing of "lifestyle" drugs. The widespread desire for—or at least acceptance of—such drugs reflects the commercial success of tapping into powerful fears of death plus hopes for "immortality." The underlying belief is that if people "do the right things"—avoid risky behaviours, eat correctly, exercise, take preventive medication, and undergo regular screening tests—they will escape major health problems and premature death. By extension, those who fail to behave wisely and to follow the medical experts’ advice will be punished by ill health and early death. The imperative to take "risk reducing" drugs is thus increased by its close fit with dominant ideologies that embrace, rather than challenge, moralistic individualism and disregard social determinants of disease.

Missing element number 5: the gendering of hormones and regulation of women’s sexuality

Finally, and perhaps most insidiously, the history of the development and promotion of HRT is inherently entangled with longstanding beliefs that sex hormones fundamentally
explain women’s and men’s behaviour and biology, that women’s “nature” and value derive from women’s capacity to bear children, and that it is in “society’s interest” to control women’s reproductive systems.43 137–144 Reflecting these beliefs, hormones that affect growth, development, and function of the reproductive system, as well as the course of pregnancy, became gendered and in the 1920s were termed “sex hormones” by the leading researchers of that era, who focused exclusively on their action on reproductive organs, tissues, and cells.41 145 Hormonal manipulation of women’s reproductive systems likewise was framed as a “natural” topic for scientific inquiry, far more so than analogous research on men’s reproductive health. If, however, “sex hormones,” had been conceptualised as one particular variety of hormones that affect cell proliferation, rather than as specialised molecules preoccupied with sex, then perhaps pharmacological change of women’s hormone levels would not have been portrayed benignly as “hormone replacement therapy,” but instead would have been more aptly seen as “hormone manipulation,” with attendant implications for cell proliferation, including increased risk of cancer.

CONCLUSION: ACCOUNTABILITY, COMPLEXITY, AND MORTALITY

In closing, understanding HRT use in the 20th century—and influencing its use in the 21st century—requires engaging not only with the science of HRT but also the social, political, and institutional context of this science. Far from a simple tale of scientific progress, or the value of randomised clinical trials over observational studies, the fundamental question we must confront is: why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already shown, three decades earlier, to be carcinogenic? To answer this question, we must engage with core issues of accountability, complexity, and fear of mortality, and the conduct of socially responsible science (see box with recommendations for future scientific research and clinical practice). There are no short cuts.

ACKNOWLEDGEMENTS

Thanks to the Radcliffe Institute for Advanced Study, Cambridge, MA for funding and hosting the exploratory seminar (hormones, women, and cancer risk: professionals and activists facing “miracle molecules”, 4–5 June 2004) that led to development of this article and also for including Dr Löwy as a Radcliffe Institute Fellow (2003–2004) for work related to this seminar’s topic.

REFERENCES

1 Writing Group for the Women’s Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women’s health initiative randomised controlled trial. JAMA 2002;288:321–33
5 Kolata G, Petersen M. Hormone replacement study a shock to the medical system. New York Times 2002;10 Jul
13 Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004;291:47–53
16 Andre M. L’impact de WHI sur les femmes. Quotidien de Médecin 2003;12 Dec
27 Auchincloss C, Haagensen DC. Cancer of the breast possibly induced by estrogenic substances. JAMA 1946;131:517–23

C Pearson, National Women’s Health Network, Washington, USA
C E Rosenberg, B G Rosenkrantz (Emerita), Department of the History of Science, Harvard University
L Rosenberg, Slone Epidemiology Center, Boston University, Boston, USA
B Seaman, Author
C Sonnenschein, A M Sato, Department of Anatomy and Cellular Biology, Tufts University School of Medicine, Boston, USA
J Thornton, Center for Ecology and Evolutionary Biology, University of Oregon, Eugene, USA
G Weisz, Social Studies of Medicine, McGill University, Montreal, Canada

Competing interests: none.

Authors’ affiliations
N Krieger, Department of Society, Human Development and Health, Harvard School of Public Health, Boston, USA
J Löwy, J-P Gaudillière, Institut National de la Santé et de la Recherche Medicale, CERMES, Villejuif, France
R Aronowitz, History and Sociology of Science Department, and Family Practice and Community Medicine, University of Pennsylvania, Philadelphia, USA
J Bigby, Community Health Programs, Brigham and Women’s Hospital, and Director, Harvard Medical School’s Center of Excellence in Women’s Health, Boston, USA
K Dickersin, The Center for Clinical Trials and Evidence-Based Healthcare, Brown University, Providence, USA
E Garner, Gynecologic Oncology, Brigham and Women’s Hospital, and Dana Farber Cancer Center, Boston, USA
C Hinestrosa, National Breast Cancer Coalition, Washington, USA
R Hubbard (Emerita), Department of Biology, Harvard University, Cambridge, USA
P A Johnson, Division of Women’s Health, Brigham and Women’s Hospital, and Connors Center for Women’s Health and Gender Biology, Boston, USA
S A Missmer, Harvard School of Public Health and Harvard Medical School, Boston, USA
J Norsigian, Our Bodies Ourselves, Boston, USA

www.jech.com
Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives


*J Epidemiol Community Health* 2005 59: 740-748
doi: 10.1136/jech.2005.033316

Updated information and services can be found at:
http://jech.bmj.com/content/59/9/740

These include:

**References**
This article cites 92 articles, 9 of which you can access for free at:
http://jech.bmj.com/content/59/9/740#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/